Abcam PLC - Cambridge, England-based life science research tools - Expects full-year 2021 revenue of GBP315 million, up 17% from GBP269.3 million the year before.
Notes that this includes a GBP2.5 million contribution of incremental revenue from BioVision, following the acquisition's completion on October 27.
Attributes the revenue growth to strong demand for its proprietary products, with in-house catalogue sales up approximately 37%.
Adds that the continued recovery in global lab activity also lifted its results.
"2021 was a year of significant innovation and growth in proteomic tools and discovery," Chief Executive Alan Hirzel comments.
Current stock price: 1,281.00 pence, up 0.6%
12-month change: down 23%
By Abby Amoakuh; abbyamoakuh@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
